Expectant management of veterans with early-stage prostate cancer.

For certain men with low-risk prostate cancer, aggressive treatment results in marginal survival benefits while exposing them to urinary and sexual side effects. Nevertheless, expectant management has been underused.

In the current study, the authors evaluated the association between various factors and expectant management use among veterans diagnosed with prostate cancer.

The authors identified men diagnosed with prostate cancer in 2008. The outcome of interest was use of expectant management, based on documentation captured through an in-depth chart review. Multivariable regression models were fit to examine associations between use of expectant management and patient demographics, cancer severity, and facility characteristics. The authors assessed variation across 21 tertiary care regions and 52 facilities by generating predicted probabilities for receipt of expectant management.

Expectant management was more common among patients aged ≥75 years (40% vs 27% for those aged < 55 years; odds ratio, 2. 57) and those with low-risk tumors (49% vs 20% for patients with high-risk tumors; odds ratio, 5. 35). There was no association noted between patient comorbidity and receipt of expectant management (P = . 90). There were also no associations found between facility factors and use of expectant management (all P>. 05). Among ideal candidates for expectant management, receipt of expectant management varied considerably across individual facilities (0%-85%; P

Patient age and tumor risk were found to be more strongly associated with use of expectant management than patient comorbidity. Although use of expectant management appears broadly appropriate, there was variation in expectant management noted between hospitals that was apparently not attributable to facility factors. Research determining the basis of this variation, with a focus on providers, will be critical to help optimize prostate cancer treatment for veterans. Cancer 2015. © 2015 American Cancer Society.

Cancer. 2015 Nov 05 [Epub ahead of print]

Christopher P Filson, Jeremy B Shelton, Hung-Jui Tan, Lorna Kwan, Ted A Skolarus, Christopher S Saigal, Mark S Litwin

Department of Urology, David Geffen School of Medicine, University of California at Los Angeles, Los Angeles, California. , Department of Urology, David Geffen School of Medicine, University of California at Los Angeles, Los Angeles, California. , Department of Urology, David Geffen School of Medicine, University of California at Los Angeles, Los Angeles, California. , Department of Urology, David Geffen School of Medicine, University of California at Los Angeles, Los Angeles, California. , Veterans Affairs Greater Los Angeles Healthcare System, Los Angeles, California. , Department of Urology, David Geffen School of Medicine, University of California at Los Angeles, Los Angeles, California. , Department of Urology, David Geffen School of Medicine, University of California at Los Angeles, Los Angeles, California.

PubMed

E-Newsletters

Newsletter subscription

Free Daily and Weekly newsletters offered by content of interest

The fields of GU Oncology and Urology are rapidly advancing. Sign up today for articles, videos, conference highlights and abstracts from peer-review publications by disease and condition delivered to your inbox and read on the go.

Subscribe